Taro Pharmaceutical Industries (NYSE:TARO) Reaches New 12-Month Low at $33.43

Shares of Taro Pharmaceutical Industries Ltd. (NYSE:TAROGet Rating) hit a new 52-week low on Thursday . The company traded as low as $33.43 and last traded at $34.00, with a volume of 68 shares changing hands. The stock had previously closed at $34.22.

Analysts Set New Price Targets

Separately, StockNews.com cut shares of Taro Pharmaceutical Industries from a “strong-buy” rating to a “buy” rating in a research report on Tuesday, June 7th.

Taro Pharmaceutical Industries Price Performance

The business’s 50-day moving average price is $36.90 and its 200 day moving average price is $40.97. The firm has a market capitalization of $1.34 billion, a price-to-earnings ratio of 14.69 and a beta of 0.66.

Taro Pharmaceutical Industries (NYSE:TAROGet Rating) last posted its earnings results on Thursday, May 26th. The company reported $0.73 EPS for the quarter, missing analysts’ consensus estimates of $0.88 by ($0.15). Taro Pharmaceutical Industries had a return on equity of 5.45% and a net margin of 15.96%. The firm had revenue of $143.26 million for the quarter, compared to analyst estimates of $147.00 million. During the same period in the previous year, the firm posted $0.81 earnings per share. As a group, sell-side analysts expect that Taro Pharmaceutical Industries Ltd. will post 3.86 earnings per share for the current year.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in the company. ARK Investment Management LLC increased its stake in shares of Taro Pharmaceutical Industries by 12.8% in the first quarter. ARK Investment Management LLC now owns 55,566 shares of the company’s stock worth $2,404,000 after buying an additional 6,307 shares during the last quarter. Murchinson Ltd. increased its stake in shares of Taro Pharmaceutical Industries by 59.2% in the fourth quarter. Murchinson Ltd. now owns 159,203 shares of the company’s stock worth $7,978,000 after buying an additional 59,203 shares during the last quarter. Invesco Ltd. increased its stake in shares of Taro Pharmaceutical Industries by 6.0% in the fourth quarter. Invesco Ltd. now owns 274,654 shares of the company’s stock worth $13,763,000 after buying an additional 15,595 shares during the last quarter. American Century Companies Inc. increased its stake in shares of Taro Pharmaceutical Industries by 20.8% in the first quarter. American Century Companies Inc. now owns 6,048 shares of the company’s stock worth $262,000 after buying an additional 1,043 shares during the last quarter. Finally, Mitsubishi UFJ Trust & Banking Corp increased its stake in shares of Taro Pharmaceutical Industries by 141.7% in the first quarter. Mitsubishi UFJ Trust & Banking Corp now owns 2,900 shares of the company’s stock worth $125,000 after buying an additional 1,700 shares during the last quarter. 12.28% of the stock is owned by institutional investors and hedge funds.

Taro Pharmaceutical Industries Company Profile

(Get Rating)

Taro Pharmaceutical Industries Ltd., a science-based pharmaceutical company, develops, manufactures, and markets prescription and over-the-counter pharmaceutical products in the United States, Canada, Israel, and internationally. The company also develops and manufactures active pharmaceutical ingredients primarily for use in its finished dosage form products.

Recommended Stories

Receive News & Ratings for Taro Pharmaceutical Industries Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Taro Pharmaceutical Industries and related companies with MarketBeat.com's FREE daily email newsletter.